Overview

A Follow-up Evaluation Study of PRI-724-1101

Status:
Completed

Trial end date:
2018-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study To evaluate the safety and efficacy of PRI-724 administration in patients with cirrhosis due to hepatitis C by 12-month follow-up.

Details

Lead Sponsor:

Komagome Hospital

Collaborator:

Prism Pharma Co., Ltd.